Pfizer Shot Just 33% Effective Against Omicron Infection, But Largely Prevents Severe Disease, South Africa Study Finds

Indonesia Berita Berita

Pfizer Shot Just 33% Effective Against Omicron Infection, But Largely Prevents Severe Disease, South Africa Study Finds
Indonesia Berita Terbaru,Indonesia Berita utama
  • 📰 Forbes
  • ⏱ Reading Time:
  • 17 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 10%
  • Publisher: 53%

Two doses of Pfizer’s Covid-19 vaccine seem to provide just 33% protection against infection with the omicron coronavirus variant, however it does largely prevent severe disease

This protection is maintained across all age groups and for people with conditions including diabetes and high blood pressure, the data suggests, though there are slightly lower levels of protection for the elderly. from the U.K., which also indicates two Pfizer shots offer less than 40% protection against infection with omicron.

to data suggesting omicron causes less severe disease, finding adults diagnosed with Covid-19 during South Africa’s fourth and current coronavirus wave were 29% less likely to be admitted to hospital than during the first wave in early 2020. Despite the race to understand the new variant, there is little hard data on omicron.

Berita ini telah kami rangkum agar Anda dapat membacanya dengan cepat. Jika Anda tertarik dengan beritanya, Anda dapat membaca teks lengkapnya di sini. Baca lebih lajut:

Forbes /  🏆 394. in US

Indonesia Berita Terbaru, Indonesia Berita utama

Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.

Pfizer tests extra COVID shot for kids under 5 in setback | AP NewsPfizer tests extra COVID shot for kids under 5 in setback | AP NewsPfizer said Friday it was changing plans and testing three doses of its COVID-19 vaccine in babies and preschoolers after the usual two shots didn't appear strong enough for some of the children. Pfizer announced the change after a preliminary analysis found 2- to 4-year-olds didn't have as strong an immune response as expected to the very low-dose shots the company is testing in the youngest children.
Baca lebih lajut »

Pfizer COVID Vaccine for Younger Children Hits SnagPfizer COVID Vaccine for Younger Children Hits SnagPfizer's COVID-19 vaccine for children ages 2 to 5 years old fizzled in clinical trials, the company said on Friday, signaling a further delay in getting a vaccine to preschoolers just as Omicron bears down on the U.S.
Baca lebih lajut »

Pfizer to Push Back Its COVID-19 Vaccine for Babies and ToddlersRead about a statement from Pfizer and BioNTech, in which they explain they will now be testing a three-dose COVID-19 vaccine for the youngest age group of babies and toddlers.
Baca lebih lajut »

In setback, Pfizer tests three doses of COVID vaccine for children under 5In setback, Pfizer tests three doses of COVID vaccine for children under 5Pfizer is testing an extra dose of its COVID-19 vaccine for babies and preschoolers after preliminary research hinted the usual two doses wouldn't be enough.
Baca lebih lajut »

CDC Recommends Pfizer, Moderna Covid-19 Vaccines Over J&J’sCDC Recommends Pfizer, Moderna Covid-19 Vaccines Over J&J’sHealth authorities said the rate of a rare but serious blood-clotting disorder associated with the Johnson & Johnson shot is higher than previously detected.
Baca lebih lajut »

CDC recommends opting for Pfizer or Moderna over J&J when there's a choiceCDC recommends opting for Pfizer or Moderna over J&J when there's a choiceThe rare blood clots are not a new safety concern, and the vaccine has already become far less common in the US.
Baca lebih lajut »



Render Time: 2025-03-04 14:59:46